5 stories
A Korean state lab reports that a tool compound called UNI418 strips out the DNA-repair proteins cancer cells use to escape PARP inhibitors. The data are preclinical: cell lines and mouse xenografts. UNI418 is not yet a drug.
CancerA phase 3 trial testing chemotherapy in ctDNA-positive colorectal cancer patients missed its primary endpoint at p=0.107, and a post-hoc reanalysis is doing the public-facing work.
CancerAn oncologist's bedside pattern, a Senate hearing, and a mechanism paper sitting in a mainstream oncology journal: the case that repeated mRNA boosters may be lifting the brakes off cancers oncologists thought they had quiet is no longer fringe enough to wave away.
CancerA single-system observational study at ASCO 2026 attached a roughly 30% lower breast-cancer rate to GLP-1 use. The randomized record already on the table is quieter.
CancerRevolution Medicines' daraxonrasib nearly doubled median overall survival versus chemotherapy in previously treated metastatic pancreatic cancer at ASCO 2026, with 8.5 months of follow-up and a two-billion-dollar Royalty Pharma deal already riding on what comes next.